CYAD Celyad Oncology SA Stock Quote

CYAD [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-1.25%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-2.48%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-20.24%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.02	Perf Half Y	-15.09%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	12.00	Perf Year	-52.76%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	3.53 - 8.80	Perf YTD	7.65%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-55.23%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	11.61%	ATR	0.18
Employees	105	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.11	Volatility	3.47% 4.24%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.01	Prev Close	3.79
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	974.66K	Price	3.94
Recom	-	SMA20	2.23%	SMA50	-1.93%	SMA200	-16.83%	Volume	10,846	Change	3.96%

Jul-05-19

Reiterated

H.C. Wainwright

Buy

$52 → $48

May-25-18

Initiated

Wells Fargo

Outperform

$44

Jan-20-22 09:40AM	Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year? Zacks
Jan-10-22 01:01AM	Celyad Oncology Provides Outlook for 2022 Business Wire
Dec-31-21 01:50PM	5 Beaten-Down Biotech Bets to Bounce Back in 2022 Zacks
01:01AM	Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire
01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
Dec-22-21 01:02AM	Celyad Oncology Announces January 2022 Conference Schedule Business Wire
01:00AM	Celyad Oncology Announces January 2022 Conference Schedule GlobeNewswire
Dec-17-21 04:05PM	Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007) GlobeNewswire
Dec-16-21 01:00AM	Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial GlobeNewswire
Dec-15-21 01:01AM	Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) Business Wire
01:00AM	Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) GlobeNewswire
Dec-13-21 01:01AM	Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition Business Wire
01:00AM	Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition GlobeNewswire
Dec-08-21 04:05PM	Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate GlobeNewswire +13.15%
04:02PM	Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate Business Wire
Dec-03-21 11:17AM	Hot Biotech Stocks: Why Celyad Oncology (CYAD) Is Soaring Higher Today InvestorPlace +32.02%
07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday InvestorPlace
01:31AM	Celyad Oncology Announces $32.5 Million Private Placement With Fortress Investment Group Business Wire
Nov-12-21 07:00AM	Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire
07:00AM	Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Business Wire
Nov-10-21 04:05PM	Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights Business Wire
Nov-04-21 09:01AM	Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition Business Wire
Nov-02-21 03:00AM	Celyad Oncology Announces November 2021 Conference Schedule Business Wire
Oct-29-21 04:05PM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
04:05PM	Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire
Oct-01-21 08:00AM	Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
08:00AM	Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting Business Wire
Sep-01-21 01:00AM	Celyad Oncology Announces September 2021 Conferences Schedule GlobeNewswire
01:00AM	Celyad Oncology Announces September 2021 Conferences Schedule Business Wire
Aug-04-21 04:01PM	Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights GlobeNewswire
Jul-30-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
01:00AM	Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire
Jul-29-21 01:00AM	Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call GlobeNewswire
Jul-20-21 04:01PM	Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day GlobeNewswire
04:01PM	Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day Business Wire
Jul-13-21 04:01PM	Celyad Oncology to Host Virtual Research & Development Webinar on July 20th GlobeNewswire
04:00PM	Celyad Oncology to Host Virtual Research & Development Webinar on July 20th Business Wire
Jul-07-21 04:01PM	Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021 GlobeNewswire
04:00PM	Celyad Oncology to Participate at the William Blair Biotech Focus Conference 2021 Business Wire
Jun-30-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
01:00AM	Celyad: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Business Wire
Jun-11-21 02:59AM	Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress GlobeNewswire
02:59AM	Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress Business Wire
May-31-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
May-26-21 01:00AM	Celyad Oncology Announces June 2021 Conference Schedule GlobeNewswire
May-19-21 01:00AM	Transparency notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007) GlobeNewswire
May-13-21 06:52AM	Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy Benzinga +8.10%
May-12-21 04:01PM	Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress GlobeNewswire
May-06-21 04:01PM	Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights GlobeNewswire -9.29%
May-05-21 01:00AM	Transparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007) GlobeNewswire
May-04-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
Apr-30-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
Apr-19-21 01:00AM	Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer GlobeNewswire
Apr-01-21 01:00AM	Celyad Oncology Announces April 2021 Conference Schedule GlobeNewswire
Mar-31-21 01:00AM	Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) GlobeNewswire
Mar-25-21 11:15AM	Celyad Oncology SA to Host Earnings Call ACCESSWIRE
Mar-24-21 04:01PM	Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights GlobeNewswire
Mar-18-21 02:00AM	Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call GlobeNewswire -9.41%
Mar-01-21 04:01PM	Celyad Oncology Announces March 2021 Conference Schedule GlobeNewswire
Feb-02-21 01:00AM	Celyad Oncology Announces February 2021 Conference Schedule GlobeNewswire
Jan-20-21 04:05PM	Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007) GlobeNewswire
04:01PM	Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007) Business Wire
Jan-18-21 01:00AM	Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium GlobeNewswire
Jan-11-21 04:01PM	Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors GlobeNewswire
Jan-07-21 01:00AM	Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital GlobeNewswire
Jan-05-21 01:00AM	Celyad Oncology Announces January 2021 Conference Schedule GlobeNewswire
Dec-15-20 04:01PM	Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC GlobeNewswire
Dec-07-20 01:00AM	Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition GlobeNewswire -10.09%
Dec-04-20 01:00AM	Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma GlobeNewswire
Dec-01-20 04:01PM	Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit GlobeNewswire
Nov-29-20 08:59AM	The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga
Nov-10-20 04:01PM	Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +6.29%
Nov-04-20 04:01PM	Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition GlobeNewswire
Nov-02-20 04:01PM	Celyad Oncology Announces November 2020 Investor Conference Schedule GlobeNewswire +11.78%
Sep-29-20 05:53PM	Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer Zacks +6.51%
07:47AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut Benzinga
01:00AM	Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC GlobeNewswire
Sep-23-20 04:01PM	Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit GlobeNewswire
Sep-22-20 04:01PM	Celyad Oncology to Host Virtual Research & Development Webinar on September 29 GlobeNewswire
Sep-14-20 01:00AM	Celyad Oncology Establishes At-the-Market Facility GlobeNewswire
Aug-26-20 01:00AM	Celyad Oncology Announces September 2020 Conference Schedule GlobeNewswire
01:00AM	Celyad Oncology Announces September 2020 Conference Schedule Business Wire
Aug-06-20 04:01PM	Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights GlobeNewswire
Aug-03-20 01:00AM	Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call GlobeNewswire
01:00AM	Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call Business Wire
Jul-15-20 10:34AM	Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate Zacks
Jul-14-20 01:00AM	Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy GlobeNewswire +11.39%
01:00AM	Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy Business Wire
Jun-10-20 01:00AM	Celyad Rebrands as Celyad Oncology GlobeNewswire +5.18%
Jun-01-20 01:00AM	Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program GlobeNewswire +10.01%
May-27-20 09:34AM	5 Health Care Stocks to Bet on as Coronavirus Woes Linger Zacks +7.54%
May-26-20 01:00AM	Celyad Announces June 2020 Conference Schedule GlobeNewswire +8.54%
May-25-20 12:00PM	All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy Zacks
May-24-20 07:00AM	3 Strong Buy Healthcare Stocks That Could Double in the Next Year TipRanks
May-07-20 01:00AM	Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +6.41%
May-06-20 01:00AM	Celyad Appoints Seasoned Industry Executives to Board of Directors GlobeNewswire
Apr-30-20 01:00AM	Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program GlobeNewswire
Apr-22-20 01:00AM	Celyad to Host Remote 2020 Ordinary General Meeting GlobeNewswire
Apr-20-20 09:06AM	Top Ranked Momentum Stocks to Buy for April 20th Zacks +6.21%
Mar-31-20 12:00PM	What Makes Celyad SA (CYAD) a New Buy Stock Zacks -7.93%

Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience